Impact Proteomics has developed a patent-pending immunoprecipitation-to-mass spectrometry (IP-to-MS) method that enables truly unbiased identification of autoantigens and cancer antigens via a single analysis in a patient-specific manner. This methodology uses a small volume of patient serum (or other antibody source) and produces unbiased, mass-spec-ready peptides for antigen identification, which enables our customers to quickly catalog the antigens associated with any given cancer or autoimmune disease.
Traditional Methods
- ELISA-based methods, immunodiffusion, immunoblotting, immunoprecipitation
-
- Targeted assays that rely on previously identified autoantigens
- No opportunity to identify novel autoantibodies
-
- Protein microarrays
-
- Limited number of potential autoantigen targets
- Proteins may not be in their native state and may not carry the same post-translational modifications as in human cells
-
The IP-to-MS Method
- Simplifies and streamlines antigen discovery
-
- Workflow completed in under 6 hours
- No specialized equipment required
-
- Unbiased approach to identify putative antigens
- Direct mass spectrometic identification of antigens
- Traditional radiolabeling replaced with ProMTag labeling
- Compatible with a range of antibody and target antigen sources
The IP-to-MS Workflow
